Clinical Trials Browser

Interventional × Breast Diseases × Trastuzumab × Clear all

NCT04784715 2026-02-20

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

Phase 3 Active not recruiting

1,157 enrolled 3 FDA

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis

NCT06886659 2025-07-22

A Study to Compare PK, Immunogenicity and Safety of Trastuzumab of Incepta Pharmaceuticals Ltd With Trastuzumab (Roche)

Phase 1 Completed

Breast Diseases, Breast Neoplasms

NCT03304080 2025-07-18

Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast

Phase 1/2 Active not recruiting

Breast Diseases, Breast Neoplasms

NCT04088110 2019-09-12

Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer

Phase 2 Unknown

Breast Diseases, Breast Neoplasms

NCT03756064 2019-08-13

Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer

Phase NA Unknown

Breast Diseases, Breast Neoplasms

NCT03910712 2019-04-10

Pyrotinib

Phase 2 Unknown

Breast Diseases, Breast Neoplasms

NCT01472146 2017-05-09

ZoNantax - Zolendronic Acid as Neoadjuvant Therapy Plus Anthracycline and Taxane in Locally Advanced Breast Cancer

Phase 2 Completed

Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site